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Abstract  
Background Sacubitril/valsartan (EntrestoTM) is a recently launched combination drug 
therapy for HF patients that has been shown to reduce mortality and patient hospitalisation. 
Aims To explore clinically relevant real-life patient data regarding prescribing of 
sacubitril/valsartan for heart failure (HF) patients in three United Kingdom hospitals in 
accordance with national guidelines. To compare prescribing rates with predicted rates 
calculated using the National Institute for Health and Care Excellence resource tool (a 
template to calculate the eligible number of patients treated with sacubitril/valsartan) and to 
describe the characteristics of patients prescribed sacubitril/valsartan at the hospital Trusts. 
Methods A retrospective multicentre study in three large UK hospital Trusts based in the West 
Midlands, an area with a high incidence of patients with HF. 
Findings A total cohort of 118 symptomatic chronic HF patients with reduced ejection fraction 
were included in the study. A high proportion of prescribers adhered to NICE guidelines for 
treatment with sacubitril/valsartan; 99% (n = 116/118) of patients had a New York Heart 
Association (NYHA) functional class of at least II; 82% (n = 96/118) had a left ventricle ejection 
fraction (LVEF) of under 35%; 100% (n= 118/118) received an angiotensin-converting enzyme 
(ACE) inhibitor or angiotensin II receptor blocker (ARB) before commencing 
sacubitril/valsartan. The mean age of men and women at the three hospitals was men 65 ± 
13, women 59 ± 12. The proportion of men prescribed sacubitril/valsartan was greater than 
women 80% compared to 20%, respectively. The vast majority of patients on the therapy 
were White British (65%). Total prescribing of sacubitril/valsartan at the three hospitals was 
295 patients, lower than expected compared to the NICE guidance resource tool, which 
predicted 1,151 eligible patients at the three hospital trusts. 
Conclusion The prescribing of sacubitril/valsartan at the Trusts generally adhered to NICE 
guidance, however the prescribing rate was lower than expected compared with the NICE 
Title page
resource tool. Further investigations into the safety and scope of application of 
sacubitril/valsartan are required to match the prescribing of sacubitril/valsartan with eligible 
patients who could benefit from the medication. 
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Introduction 
Approximately 1.37% (900,000 people) of the UK population suffer from Heart Failure (HF)1-3. HF is 
a clinical term that encompasses a range of different diseases of the heart which lead to lowered 
cardiac output and/or high intracardiac pressure and therefore inefficient perfusion to the body4. In 
HF there is a large comorbidity burden including structural or functional heart abnormalities that 
can exacerbate the syndrome4. There are 530,133 people on the UK national heart failure register, 
including 47,238 from the West Midlands5. Five percent of all emergency admissions include adult 
patients with HF, either as the cause or a complication, with an average length of hospital in-patient 
stay of 6-9 days in a general medical or cardiology ward, respectively2. HF is also associated with 
various co-morbidities and early death4. Therefore, HF causes considerable economic burden on 
both the patient and the healthcare system, due to extensive health economy costs. Approximately 
2% of the NHS budget is used in the standard and hospitalised treatment and aftercare of patients, 
as well as the reduced number of HF patients that return to full employment6,7. Further strain on 
the individual post-HF results from unemployment, low quality of life and poor prognosis4.  
Treatments for HF, such as beta-blockers, aldosterone blockers, angiotensin-converting enzyme 
inhibitors (ACEi) and Angiotensin II receptor blockers (ARBs) were developed in the 20th century and 
have had substantial effects on patients’ health, by acting on different targets8. In this study, 
prescribing practices of a recently launched dual drug therapy for HF called EntrestoTM 
(sacubitril/valsartan) were investigated. 
The 2014 PARADIGM-HF trial led to a breakthrough in HF treatment8 with the release of 
sacubitril/valsartan in January 2016. A NICE guideline, on its use in heart failure with reduced 
ejection fraction (HFrEF) and a NICE resource tool, on the expected patient uptake, was published 
in April 20161. 
 
Mode of action of sacubitril/valsartan 
Sacubitril/valsartan (Entresto™) is a sodium salt complex (see Figure 1) and the first medication of a 
new class; combining an angiotensin II type-1 receptor antagonist (Angiotensin receptor blocker, 
ARB), valsartan, and a neprilysin inhibitor (NEPi), sacubitril, which together is known as a new class 
of ARNi (Angiotensin receptor-neprilysin inhibitor). 
 
Valsartan acts on the renin-angiotensin-aldosterone system. The mode of action of this molecule is 
to compete with angiotensin II by binding to the type-1 angiotensin II receptor (AT1R). This 
therefore prevents the effects of angiotensin II (Ang II), which include vasoconstriction, increased 
fibrosis, sodium retention, cell proliferation and oxidative stress. Upon oral dosing, EntrestoTM, via 
dissolution and absorption, delivers systemic exposure to valsartan and sacubitril. Sacubitril is an 
inactive pro-drug that is enzymatically cleaved after absorption (at the ethyl ester position to form 
the carboxylic acid), delivering Sacubitrilat, the active metabolite which inhibits neprilysin. 
Neprilysin is a metalloprotease, usually membrane-bound that when released from the membrane 
acts as a catalytic enzyme that degrades natriuretic peptides (atrial natriuretic peptide ANP) and 
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(brain natriuretic peptide BNP) as well as bradykinin. By blocking this action, sacubitrilat allows 
these molecules to continue to have their effects of natriuresis, vasodilation and reducing fibrosis 
on the body. 
 
 Figure 1- EntrestoTM (sacubitril/valsartan) combination and active metabolite. 
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Combination of valsartan and sacubitril  
When valsartan is combined with sacubitril studies have determined that the plasma concentration 
of valsartan is 40% higher than when delivered without Sacubitril 8-13. However, the mechanism of 
this increase in bioavailability of valsartan remains unclear as valsartan is known to be excreted 
largely as the unchanged compound and is minimally metabolized in human and this is most likely 
an effect of the co-crystallised formulation in EntrestoTM versus valsartan alone14. Among the 
cytochrome P450 (CYP) enzymes, CYP2C9 is the only CYP isoform responsible for 4-position 
hydroxylation of valsartan in human liver microsomes (HLMs)15,16. 
In summary, EntrestoTM inhibits neprilysin and blocks angiotensin II type-I receptor. Sacubitril 
increases the levels of peptides that are normally degraded by neprilysin. Valsartan inhibits the 
effects of angiotensin II by blocking the AT1 receptor and by inhibiting the release of angiotensin II-
dependent aldosterone. 
 
Clinical Evidence for sacubitril/valsartan 
The PARADIGM-HF study, conducted in 2014 on 8442 subjects, found that sacubitril/valsartan 
significantly improved patient outcomes. The medication reduced deaths from cardiovascular 
causes from 16.5% to 13.3% (P-value <0.001), and rehospitalisation by 21% (P<0.001), when 
compared to enalapril the current first line therapy17. 
Sacubitril/valsartan has been available for treating HF patients through the NHS since January 2016, 
via the early access to medicines scheme (EAMS).  
Within the NICE recommendations18 for the use of sacubitril/valsartan, there are three criteria for 
which patients to select for treatment; those with: 
1. An NYHA functional class of II or above 
2. A LVEF of 35% or below 
3. Stabilised on an ARB or ACE inhibitor 
This guideline set a standardised approach to therapy, based on clinical evidence and would lead to 
optimal treatment of HF patients18. Although healthcare providers have a duty to exercise their 
own judgement according to individual patient needs, an understanding of the NICE 
recommendations is expected18. NICE released a resource impact tool in April 2016, demonstrating 
the cost-effectiveness and expected prescribing rates of sacubitril/valsartan over the 5 year period 
following its publication18. The NICE resource tool, a template to calculate the eligible number of 
patients treated with sacubitril/valsartan per year, found that within the UK 108,000 people met 
the NICE criteria for treatment for sacubitril/valsartan, described above, however as this drug is 
relatively new, the expected prescribing rate is estimated to be 64,500 by 2020/21 18. The NICE 
resource tool also calculated that annual treatment of sacubitril/valsartan for one patient would 
cost £1,194 which was a better health economic proposition than hospitalisation which was 
estimated to cost £2,698 18. 
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Aims and Objectives 
 
To explore prescribing practices of sacubitril/valsartan at three UK hospitals in accordance with 
national guidelines.  
 
Specific objectives: 
 To determine adherence to NICE guideline (TA388) when prescribing sacubitril/valsartan 
therapy. 
 To compare prescribing rates of sacubitril/valsartan at three hospitals to the predicted 
prescribing rates calculated when using the NICE resource tool.  
 To explore differences and variations between the Trusts regarding their prescribing of 
sacubitril/valsartan.  
 To describe the characteristics of patients prescribed sacubitril/valsartan. 
Methods 
A multicentre retrospective study was conducted over a 6 month period of the use of 
sacubitril/valsartan at three large and well established cardiac centres in the West Midlands area 
with a high proportion of HF patient admissions. The study proforma was adapted from NICE 
guidelines1. After ethical approval of all relevant bodies including The University of Birmingham and 
the respective hospitals, the study was carried out by a researcher under supervision of the 
stakeholders (supervising specialist pharmacist and heart failure team’s at each hospital Trust) on 
the hospital premises. Hospital databases were accessed to gather information, from the initiation 
of prescribing sacubitril/valsartan (first prescription issued for a patient) up until the end date of 
the study which was January 2018 at each individual hospital.  
Inclusion Criteria: patients with symptomatic chronic HF with reduced ejection fraction prescribed 
sacubitril/valsartan. 
The following patient information was collected: NYHA functional class, LVEF, and prior HF 
medication. Furthermore, data on sacubitril/valsartan treatment was gathered: this included side 
effects, re-admission, discontinuation, and patient demographic data. In addition, blood pressure 
data, heart rate, eGFR, potassium and sodium levels as well as patients’ baseline medication (beta-
blockers, mineralocorticoid antagonists, diuretics) and devices (implantable cardioverter-
defibrillator (ICD), cardiac resynchronization therapy (CRT) and pacemakers (PPM)) were collected. 
All data was anonymised, in line with NHS information governance protocols to protect patient 
confidentiality and adherence to hospital policies, and then compiled for analysis, which was 
conducted by using Microsoft Excel and further processed and analysed with IBM Statistical 
Package for Social Science (SPSS) 24.  
n1=number of included patients in hospital 1, n2=number of included patients in hospital 2, n3=number of included 
patients in hospital 3, nt= total (t) number of patients on Entresto™  
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Results 
The study was conducted over a period of six months and the data collection period was from 
23/10/17 to 20/1/2018 at the three different UK hospital trusts: 
 
Sample  
A total cohort of 118 patients were included in the study (Tables 1 & 2); 20 patients from hospital 1 
(n1), 37 patients from hospital 2 (n2) and 61 patients from hospital 3 (n3). The mean age of men and 
women from the combined findings at the three hospitals was women 59 ± 12, men 65 ± 13 all 64 
+13. At the time of the study 198 patients were prescribed sacubitril/valsartan at hospital 3, 
however, only raw data for 61 patients was available to the researcher to collect and analyse within 
the time frame of the study.  
The majority of patients were within the age ranges of 61 to 70 years and those over 70 years old, 
31% and 30% respectively (see figure 2 below). The proportion of men was greater than women 
80% compared to 20%, respectively. The vast majority of patients prescribed sacubitril/valsartan 
therapy were white British (65%), followed by South Asians (10%) then other white backgrounds 
(9%). Fewer were undocumented (6%), black Caribbean (4%), or either mixed white and black 
Caribbean or black African background (3% both). 
 
Adherence to NICE guideline 
Determining adherence to NICE guidelines for use of sacubitril/valsartan for treating symptomatic 
chronic HF patients with reduced ejection fraction, three criteria were reviewed: NYHA of II or 
above, LVEF of 35% or below, and stabilisation on an ACE inhibitor or ARB. Data below details 
adherence to guidelines for each criteria mentioned in the NICE guideline1 for all three hospitals 
combined. Adherence to the NICE guideline was high overall.   
 
New York Heart Association classification (NYHA): 
In all three hospitals the majority of patients were within the NYHA class II category 65% (n1=20), 
65% (n2=37), 44% (n3=61), with NYHA class III being the next most common 30% (n1=20), 27% 
(n2=37), 31% (n3=61). There were no patients with NYHA class II-III at hospital 1, 5% (n2=37), 15% 
(n3=61) in hospital 2 and 3 respectively. NYHA class III-IV was only encountered at hospital 3 (n3=4). 
Two cases of contraventions of the NICE guidelines were found. In hospital 1, a patient was treated 
despite having a NYHA function class I and in hospital 3 one patient’s NYHA class was not 
documented. 
 
Left Ventricle Ejection Fraction: 
In combined findings from the three hospitals the majority of patients fell under the 20-30% LVEF 
range (30%, (n1=20); 38%, (n2=37); 31%, (n3=61). There were few patients with no identified LVEF 
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14% (nt=17/118) or an LVEF of over 35% (4%, nt =5/118), which is not in-line with NICE guidelines. 
Hospital 2 treated two patients with a LVEF over 35% and three with unknown LVEF. Hospital 3 
treated two patients with a LVEF over 35% and 14 withunknown LVEF (23%, n3=61). Hospital 1 
complied with the NICE guidelines regarding LVEF. 
 
Prior use of ACE inhibitors or ARB: 
The last criteria reviewed was prior stabilisation of the HF patients on an ACEi or ARB. The study 
showed that in total 71% (nt=83/118) of the patients in the Trusts were already stabilised on an ACE 
inhibitor, ramipril (44%), perindopril (24%), lisinopril (2%), and enalapril (1%), and 29% (nt=35/118) 
were already stabilised on an ARB,  valsartan (1%), losartan (15%) and candesartan (13%), prior to 
prescribing sacubitril/valsartan.  
 
Side effects 
The main side effects mentioned in NICE guideline include hypotension, hyperkalaemia and renal 
impairment. On average 65% (nt= 76/118) of patients within this study experienced one of the 
following side effects dizziness, hypotension, renal impairment and fatigue and were noted in all 
Trusts. There was a large disparity in the documentation of side effects and their prevalence 
between the three Trusts.  
 
Rehospitalisation 
The rate of re-hospitalisation in hospital 1 was 5% (n1=20) compared with hospital 2 3% (n2=37). 
Difficulties in breathing, shortness of breath, orthopnoea and paroxysmal nocturnal dyspnoea 
where reported reasons responsible for re-hospitalisation in hospital 1. A case in hospital 2 led to 
discontinuation of sacubitril/valsartan, the patient was hospitalised due to shortness of breath, 
chest pain and development of acute kidney injury (AKI). At hospital 3, 28 patients were seen in 
Accident and Emergency during sacubitril/valsartan treatment. However only 15 cases could be 
identified to be categorically caused by HF presenting complaints such as chest pain, shortness of 
breath and decompensated HF.  
 
 
Discontinuation 
None of the patients studied at hospital 1 discontinued their sacubitril/valsartan medication. 
However, at hospital 2, there were three cases 8% (n1=37), two cases of hypotension and one of 
AKI. At hospital 3, there were nine cases 15% (n2=61) of discontinuation: three were due to death 
(one death was due to AKI), five from adverse events and one due to a prescriber error. Of those 
where discontinuation was due to adverse events; one was due to an AKI, one suffered from kidney 
impairment, two patients had a potential allergic reaction and one patient suffered from recurrent 
hypotension which led to discontinuation of sacubitril/valsartn.  
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Hospital and prescriber uptake of Entresto 
 
Approximately 12 months after NICE TA3881, the guideline for the use of sacubitril/valsartan was 
published (27/04/2016), prescribing at hospital 1 began (Table 3). The prescribing uptake slowly 
increased from April 2017 with a steady increase in uptake thereafter and there has been further 
prescribing of sacubitril/valsartan since the completion of this study; 25 patients overall. Prescribers 
in hospital 2 started prescribing sacubitril/valsartan in July 2016, three months after publication of 
NICE TA388, after two plateau phases prescribing increased steadily. At the end of the study 52 
patients were prescribed sacubitril/valsartan at hospital 2. At hospital 3 the prescribing of 
sacubitril/valsartan started in February 2016, two months before the NICE TA388 was published. 
Since September 2016 prescribing has increased and persisted until the end of this study. The NICE 
resource tool predicted that approximately 404 patients at hospital 1, 253 patients at hospital 2 and 
494 patients at hospital 3 would have met the criteria for treatment detailed in NICE TA388 and 
therefore could have been potential candidates for the treatment of sacubitril/valsartan (Figure 2). 
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Figure 2 Prescribing uptake onto sacubitril/valsartan at the three hospitals 
Prescribing uptake onto sacubitril/valsartan at Hospital 1 
 
Prescribing uptake onto sacubitril/valsartan at Hospital 2 
 
Prescribing uptake onto sacubitril/valsartan at Hospital 3 
 
 
 
 
 
10 
 
 
Discussion 
Statement of principal findings 
The development of sacubitril/valsartan was preceded by years of research into the 
pathophysiology of HF. Along with the development of earlier  medicines for treatment of HF, for 
example ACE inhibitors, ARBs and other therapeutic drug classes, this fed directly into the design of 
this molecule. There is a firm rationale behind the choice of the two molecules that compose 
EntrestoTM, which takes advantage of the two different mechanisms of action of valsartan and 
sacubitril to affect a dual response in treating HF. 
The efficacy of sacubitril/valsartan, evidenced in the literature shows a definite benefit in patient 
outcomes to reduce mortality and re-hospitalisation17. It is also proven to be within accepted cost-
effectiveness limits (<£20,000 per QALY), despite costing significantly more than the current generic 
treatment available17. 
At the three Trusts in the study it was found that the overall majority of prescribers (93%) adhered 
to the three main criteria of NICE guidelines: NYHA functional class of II or above, LVEF of 35% or 
below, and prior stabilisation of an ACEi or ARB. However, a large difference was observed in the 
prescribing practices of sacubitril/valsartan therapy between the trusts which could be due to a 
variety of factors including local delays in implementing NICE guidelines.  
There were differences in the three hospitals regarding the time of initiation of the first prescription 
issued for sacubitril/valsartan and the number of patients prescribed the medication. Explanations 
for this disparity could be due to hospital prescribing policies differing from trust to trust, and 
prescribing habits, such as inertia to prescribing a new medication among the prescribers, differing 
between individuals, as well as knowledge of the medication and its use. This study did not take 
into account the input of prescribers or hospital policy and the influence of Clinical Commissioning 
Groups with regards to sacubitril/valsartan so a solid conclusion cannot be drawn. Nevertheless, a 
qualitative study including interviews with prescribers investigating their knowledge of guidelines 
and local hospital policies, in addition to their experiences with patients when prescribing 
sacubitril/valsartan would be important to recommend.  
Compared to the estimation using the NICE resource tool, in all hospitals there were substantially 
fewer patients prescribed sacubitril/valsartan than anticipated. The NICE resource tool predicted 
prescribing uptakes varying from 253 to 494 patients (404, 6%, n1t=25; 253, 21%, n2t=52; 494, 44%, 
n3t=218), whereby the trusts only had a total uptake which varied from 25 to 218 patients. 
Therefore, there is potential to improve prescribing practices and recruiting HF patients which meet 
the criteria for this new medication. This is particularly important as new findings are emerging 
from recent studies showing a distinct post-sacubitril/valsartan initiation improvement in HF 
symptoms and a reduction in subsequent hospitalizations 19, which supports the findings from the 
PARADIGM-HF study8. 
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Regarding the sample of patients included in this study the average age for both men and women 
was similar, at around 60 years old and around 5% (7/118) of patients were below the age of 40 
years. However there was variability in the age of the patients on sacubitril/valsartan at the three 
hospitals regardless of gender. Statistics from the British Heart Foundation in 2017 showed 
prevalence of HF to be 0.8% regardless of gender. With earlier research showing the prevalence of 
heart failure in 2013, was slightly higher in men of all ages than women of all ages 1.22% vs. 0.76% 
20, 21. Furthermore, HF is not common in younger people under 50 years and prevalence and 
incidence increases with age. Population‐based studies have shown that the prevalence of HF is 
2.2% and increases from 0.7% in persons aged 45 through 54 years to 8.4% for those aged 75 years 
or older22, a similar trend was observed in this patient sample. 
In this study the proportion of men with HF prescribed sacubitril/valsartan was greater than women 
80% compared to 20% respectively. There are several factors which could influence  this 
proportion, such as women being twice as likely as men to develop HF with preserved ejection 
fraction (HFpEF) making those women ineligible for sacubitril/valsartan treatment23. Literature also 
shows a gender bias in receiving HF treatments, for example ACE inhibitors and beta blockers. 
Currently, despite a lack of evidence that ACE inhibitors or beta blockers have any less effect in 
women, they are less likely to receive such therapies in clinical practice, even after correction for 
age bias24. In addition being stabilised on an ARB or ACE inhibitor before commencing treatment on 
sacubitril/valsartan is an essential criteria for prescribing, this may have also accounted for the 
discrepancy in the proportion between male and female patients at the studied hospitals. 
In this study the largest proportion of patients prescribed sacubitril/valsartan therapy were White 
British, 65%, followed by South Asian, 10%, then other White backgrounds, 9%. There is limited 
information available on a link between ethnicity and HF, while there is more research on ethnicity 
and cardiovascular disease in general, especially South Asian patients having increased risk of 
developing coronary heart disease. A recent large UK study including a cohort of more than 1 
million patients with cardiovascular disease found an expected substantial predominance of 
coronary heart disease presentations in South Asians and predominance of stroke presentations in 
Black patients, but no ethnic differences in presentation with heart failure compared to White 
patients 25. Furthermore an American study, found that African Americans were more likely than 
Hispanic, White and Chinese Americans to develop chronic HF, 4.6 compared to 3.5, 2.4 and 1.0 per 
1,000 person years respectively, however it was concluded that this was due to the disparity in the 
incidence of diabetes and hypertension as well as socioeconomic differences rather than race 26. 
Studies investigating ethnic differences in the prescribing and response to sacubitril/valsartan in 
patients with HF in different ethnic groups would be of interest especially since an abundance of 
previous evidence has shown ethnic differences in the response to ACE inhibitors and ARBs 27.  
Regarding the incidence of side effects the sample size in this study was small and no clear 
conclusion could be made due to inconsistency in the documentation of side effects in the 3 
hospital databases. This could be due to different prioritisation of recording of side effects by the 
differing trusts. Cough as a main side effect was documented by hospital 3 could be caused by HF or 
sacubitril/valsartan as well as viral or bacterial infection. Due to most of the patients having 
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comorbidities, other medications could have contributed to side effects recorded. Furthermore, 
other side effects documented including light-headedness, dizziness and nausea in one hospital 
were recorded as presyncopal symptoms or vasovagal symptoms in another hospital which made it 
difficult to analyse and categorise side effects from the collected data.  
Hypotension, fatigue and renal impairment were the main side effects identified among the patient 
population included in this study. Similar results were reported in a recent pharmacovigilance study 
in France (including 8845 patients)28 showing that patients on sacubitril/valsartan had common side 
effects including hypotension, renal impairment and shortness of breath. The results of this study 
are in agreement with this large pharmacovigilance study and also with side effects reported from 
NICE guidelines18.  
 
Unanswered questions and future research 
There are many avenues for the future research on sacubitril/valsartan as this medication is new 
and its use is emerging within HF patient treatment but there are many gaps in the field, where 
additional studies could aid in the safe administration of the product. For example, the ongoing 
trials of its efficacy in HF preserved ejection fraction, chronic kidney disease (CKD) and preventing 
HF events after MI; PARAGON-HF29, UK HARP-III 30 and PARADISE-MI31 respectively, are examples.   
This study could be expanded to include UK-HF population and enable comparisons to be made 
between regions. There is scope to expand further and incorporate partners internationally. A study 
with a longer duration could be attempted to compare prescribing uptake against the 5-year NICE 
prediction with the resource tool.  
Conclusions 
The prescribing of sacubitril/valsartan at the sample trusts generally adhered to NICE guidance, 
however prescribing rates were lower than expected compared with the predictions from the NICE 
resource tool. Further investigations into the safety and scope of application of sacubitril/valsartan 
are required to increase the appropriate prescribing of sacubitril/valsartan; to meet the predicted 
number of patients who could potentially benefit from this medication in accordance with the NICE 
resource tool. 
 
Key points 
 First multicentre study of sacubitril/valsartan in the West Midlands, investigating prescribing 
practices and adherence to NICE guideline TA388 1. 
 Study criteria were developed through discussion with Consultants at the West Midland 
Cardiac Pharmacists Group (WMCPG) and patient and public involvement in education at 
the University of Birmingham. 
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 The results add significantly to the limited data regarding prescribing practices of 
sacubitril/valsartan. 
 Relatively limited sample size of 118 patients. 
 Documentation differed from Trust to Trust, this influenced data collection.  
Reflective questions 
What is already known about this subject? 
Sacubitril/valsartan is a recently launched combination drug therapy for HF patients that has been 
shown to reduce mortality and patient hospitalisation based on the PARADIGM-HF clinical study. 
 
What does this study add? 
This study adds to the very limited data on sacubitril/valsartan and provides new insight into 
hospital prescribing practices, patterns and clinical characteristics of patients on 
sacubitril/valsaratan. Furthermore, this is the first multi-centre study that also compares uptake to 
the NICE resource tool and NICE clinical guidelines. 
 
How might this impact on clinical practice? 
As can be seen from the study prescribing of sacubitril/valsartan was lower than expected despite 
the clinical benefit mainly reduction in patient hospitalisations and mortality. The study may impact 
on physicians prescribing habits by providing information of current prescribing and prescriber 
uptake. 
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Table 1 – Demographic Data of all patients included into the study 
 Hospital 1 
(n1=20) 
Hospital 2 
(n2=37) 
Hospital 3 
 (n3=61) 
Total 3 
hospitals 
 
Age [years] < 40  3 2 2 Mean 
(n1-3) 
63.78 
 40 - 50 1 7 2 
 51 - 60 7 10 13 
17 
 
 61 - 70 6 13 17                                 
Standard 
deviation 
(n1-3) 
13.27 
 
 > 70 3 5 27 
Gender Male 15 32 48 
 Female 5 5 13 
 
Ethnicity  % Total 3 
hospitals 
 White British 17  23 37  65% 
 South Asian 1 2 9  10% 
 Mixed White&Black 
Caribbean 
1 2 0  3% 
 Black Carribbean 1 3 0  4% 
 Black African 0 3 0 3% 
 White Other 0 4 7   9% 
 Not documented 0 0 7 6% 
 
Comorbidities Previous Stroke/TIA 1 3 8 
 COPD 3 3 5 
 Hypertension 4 15 31 
 Diabetes 4 15 22 
 VHD 5 1 12 
 Nonvalvular AF 7 10 27 
 Previous Myocardial 
Infarction 
9 10 18 
 CHD 16 29 38 
Baseline  Systolic BP [mmHg] 118±15 126±15 126±21 
average Diastolic BP [mmHg] 70±11 76±10 77±11 
measurements Heart rate [beats/min] 71±10 70±10 73±12 
 eGFR [mL/min/1.72] 75±15 68±15 n/a 
 Potassium level 4.4±0.4 4.6±0.5 4.3±0.5 
 Sodium level 138±2 138±2 139±4 
Baseline  Implant. cardioverter-
defibrillator  
7 19 19 
Medication 
and Devices 
Cardiac resynchronization 
therapy 
4 4 4 
Pacemaker 0 1 1 
 Beta-blockers 20 36 61 
 Diuretics 16 27 51 
18 
 
 Mineralocorticoid 
antagonists 
14 28 45 
New York  
Heart 
Association 
classification 
NYHA I 1 0 0 
NYHA II 13 24 27 
NYHA II - III 0 2 9 
 NYHA III 6 10 19 
 NYHA III - IV 0 0 4 
 NYHA IV 0 1 1 
 Unknown 0 0 1 
Left Ventricle 
Ejection 
Fraction 
LVEF <20% 5 12 9 
LVEF 20-30% 6 14 19 
LVEF 31-35% 9 6 17 
 LVEF >35% 0 2 2 
 Unknown 0 3 14 
Prior use of 
ACE inhibitor 
or ARB 
Candesartan 3 6 7* 
Enalapril 0 0 1 
Lisinopril 0 0 3 
 Losartan 2 2 13 
 Perindopril 2 16 11 
 Ramipril 13 12 27* 
 Valsartan 0 1 0 
*one patient in hospital 3 was on Ramipril and Candesartan 
 
Table 2 –Summary of results of the study 
  Hospital 1 
(n1=20) 
Hospital 2 
(n2=37) 
Hospital 3 
(n3=61) 
Readmission Total readmission 1 1 28 
 Readmission caused by HF 1 1 15 
Discontinuation  0 3 9 
Prescriber 
uptake 
Study 10/2017 
 
25 52 218 
 NICE Resource tool1 404 253 494 
1NICE Resource tool gives an estimated number of eligible patients for sacubitril/valsartan each year 
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Table 3 - Number of people eligible for treatment in each of the three trusts provider population, 
adapted from NICE Resource impact report: Sacubitril/valsartan for treating symptomatic chronic 
heart failure with reduced ejection fraction (TA388) 2016. 
 
Population 
 
 
Proportion 
(percentage 
from hospital 
1,2,3 
respectively) 
Hospital 1 
(2011) 
Hospital 2 
(2014) 
Hospital 3 
(2011) 
Total catchment population - 847,433a 530,000b 1,037,004a 
People with heart failure 0.76% 6,440 4,028 7,881 
People with heart failure 
with reduced ejection 
fraction 
72.00% 4,637 2,900 5,674 
People with heart failure 
with reduced ejection 
fraction and NYHA class II to 
III symptoms 
71.00% 3,292 2,059 4,029 
People with heart failure 
with reduced ejection 
fraction and NYHA class II to 
III symptoms with a left 
ventricular ejection fraction 
of 35% or less 
59.50% 1,959 1,225 2,397 
People with heart failure 
with reduced ejection 
fraction and NYHA class II to 
III symptoms with a left 
ventricular ejection fraction 
of 35% or less and taking an 
ACE inhibitor or ARB 
85.95% 1,684 1,053 2,060 
People having 
sacubitril/valsartan from 
year 2 
24.00% 404 253 494 
This table is adapted from the NICE Resource Tool for guideline TA388 (NICE, 2016b) 
a Value taken from National Clinical Analysis and Specialised Application Team NATCANSAT (2012) 
b Value taken from CQC -Care Quality Commission (2014) 
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Supplementary material  
Table -4- Data collection tool for the retrospective study of the use of valsartan/sacubitril in heart failure  
Hospital:  Anonymised Patient ID:  Age: 
Gender: Ethnicity:  
Tick the relevant box and/or fill out the information needed under Details.  
No. Questions: Yes No Details: 
 NICE Guidelines    
1. What was the NYHA classification of the patient prior to 
initiation of Entresto? 
- -  
2. What was the LVEF classification of the patient prior to 
initiation of Entresto? (%) 
- -  
 Refer to question 5 for ACE inhibitor/ARB use    
     
 Patient Medical History    
3. Does the patient have any comorbidities?     
4. If so, specify which of the following the patient has: - -  
A Diabetes    
B Previous Myocardial Infarction (MI)    
C Non-valvular Atrial Fibrillation (NVAF)    
D Valvular Heart Disease (VHD)    
E Previous Stroke or Transient Ishaemic Attack (TIA)    
F Hypertension    
G Device e.g. CRT-D/ICD    
H Coronary Heart Disease (CHD)    
I Chronic Obstructive Pulmonary Disease (COPD)    
J Other (Please state) - -  
5. Was the patient on an ACE inhibitor/ARB prior to 
initiation of Entresto?   
Document drug and dose 
  
 
6. Was the patient on a Beta-blocker (BB) prior to initiation 
of Entresto?    
Document drug and dose 
  
 
7. Was the patient on a diuretic prior to initiation of 
Entresto?  
Document drug and dose 
- - 
 
8. Was the patient on a Mineralocorticoid Receptor 
Antagonist (MRA) prior to initiation of Entresto? 
Document drug and dose 
  
 
9. If the patient wasn’t prescribed an MRA, which of the 
following reasons was the cause: 
- - 
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A Hyperkalaemia    
B Hypotension    
C Renal function    
D Sexual side effects/gynaecomastia    
E Other (please state) - -  
F No reason stated     
     
 Entresto Therapy    
10. Date of initiation of Entresto - -  
11. How long has the patient been on Entresto?  
Date of initiation to date of audit or date of 
discontinuation  
  
 
12. Date of discontinuation (if applicable) 
Document reason and alternative prescribed 
- - 
 
13. How did the dose of Entresto change over time? 
 
Dose on initiation: date 
Dose on optimisation: date 
Dose when stabilised: date 
- - 
 
14. What was the NYHA classification of the patient while on 
Entresto? 
- - 
 
15. How many follow-up appointments did the patient have 
with the HF team?  
- - 
 
16. At each point of contact, what was the patient’s 
CrCl (ml/min)? 
K? 
Na? 
BP? 
 
- - 
 
 
  
 
 
 
Figure 1- EntrestoTM (sacubitril/valsartan) combination and active metabolite. 
 
 
 
Figure (i.e. diagram, illustration, photo) Click here to access/download;Figure (i.e. diagram, illustration,
photo);fig1.docx
Figure 2 Prescribing uptake onto sacubitril/valsartan at the three hospitals 
Prescribing uptake onto sacubitril/valsartan at Hospital 1 
 
Prescribing uptake onto sacubitril/valsartan at Hospital 2 
 
Prescribing uptake onto sacubitril/valsartan at Hospital 3 
 
 
 
 
 
 
Figure (i.e. diagram, illustration, photo) Click here to access/download;Figure (i.e. diagram, illustration,
photo);fig2.docx
Table 1 – Demographic Data of all patients included into the study 
 Hospital 1 
(n1=20) 
Hospital 2 
(n2=37) 
Hospital 3 
 (n3=61) 
Total 3 
hospitals 
 
Age [years] < 40  3 2 2 Mean 
(n1-3) 
63.78 
                                
Standard 
deviation 
(n1-3) 
13.27 
 
 40 - 50 1 7 2 
 51 - 60 7 10 13 
 61 - 70 6 13 17 
 > 70 3 5 27 
Gender Male 15 32 48 
 Female 5 5 13 
 
Ethnicity  % Total 3 
hospitals 
 White British 17  23 37  65% 
 South Asian 1 2 9  10% 
 Mixed White&Black 
Caribbean 
1 2 0  3% 
 Black Carribbean 1 3 0  4% 
 Black African 0 3 0 3% 
 White Other 0 4 7   9% 
 Not documented 0 0 7 6% 
 
Comorbidities Previous Stroke/TIA 1 3 8 
 COPD 3 3 5 
 Hypertension 4 15 31 
 Diabetes 4 15 22 
 VHD 5 1 12 
 Nonvalvular AF 7 10 27 
 Previous Myocardial 
Infarction 
9 10 18 
 CHD 16 29 38 
Baseline  Systolic BP [mmHg] 118±15 126±15 126±21 
average Diastolic BP [mmHg] 70±11 76±10 77±11 
measurements Heart rate [beats/min] 71±10 70±10 73±12 
 eGFR [mL/min/1.72] 75±15 68±15 n/a 
 Potassium level 4.4±0.4 4.6±0.5 4.3±0.5 
 Sodium level 138±2 138±2 139±4 
Table Click here to access/download;Table;Table 1.docx
Baseline  Implant. cardioverter-
defibrillator  
7 19 19 
Medication 
and Devices 
Cardiac resynchronization 
therapy 
4 4 4 
Pacemaker 0 1 1 
 Beta-blockers 20 36 61 
 Diuretics 16 27 51 
 Mineralocorticoid 
antagonists 
14 28 45 
New York  
Heart 
Association 
classification 
NYHA I 1 0 0 
NYHA II 13 24 27 
NYHA II - III 0 2 9 
 NYHA III 6 10 19 
 NYHA III - IV 0 0 4 
 NYHA IV 0 1 1 
 Unknown 0 0 1 
Left Ventricle 
Ejection 
Fraction 
LVEF <20% 5 12 9 
LVEF 20-30% 6 14 19 
LVEF 31-35% 9 6 17 
 LVEF >35% 0 2 2 
 Unknown 0 3 14 
Prior use of 
ACE inhibitor 
or ARB 
Candesartan 3 6 7* 
Enalapril 0 0 1 
Lisinopril 0 0 3 
 Losartan 2 2 13 
 Perindopril 2 16 11 
 Ramipril 13 12 27* 
 Valsartan 0 1 0 
*one patient in hospital 3 was on Ramipril and Candesartan 
 
Table 2 –Summary of results of the study 
  Hospital 1 
(n1=20) 
Hospital 2 
(n2=37) 
Hospital 3 
(n3=61) 
Readmission Total readmission 1 1 28 
 Readmission caused by HF 1 1 15 
Discontinuation  0 3 9 
Prescriber 
uptake 
Study 10/2017 
 
25 52 218 
 NICE Resource tool1 404 253 494 
1NICE Resource tool gives an estimated number of eligible patients for sacubitril/valsartan each year 
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Table 3 - Number of people eligible for treatment in each of the three trusts provider population, 
adapted from NICE Resource impact report: Sacubitril/valsartan for treating symptomatic chronic 
heart failure with reduced ejection fraction (TA388) 2016. 
 
Population 
 
 
Proportion 
(percentage 
from hospital 
1,2,3 
respectively) 
Hospital 1 
(2011) 
Hospital 2 
(2014) 
Hospital 3 
(2011) 
Total catchment population - 847,433a 530,000b 1,037,004a 
People with heart failure 0.76% 6,440 4,028 7,881 
People with heart failure with 
reduced ejection fraction 
72.00% 4,637 2,900 5,674 
People with heart failure with 
reduced ejection fraction and 
NYHA class II to III symptoms 
71.00% 3,292 2,059 4,029 
People with heart failure with 
reduced ejection fraction and 
NYHA class II to III symptoms 
with a left ventricular 
ejection fraction of 35% or 
less 
59.50% 1,959 1,225 2,397 
People with heart failure with 
reduced ejection fraction and 
NYHA class II to III symptoms 
with a left ventricular 
ejection fraction of 35% or 
less and taking an ACE 
inhibitor or ARB 
85.95% 1,684 1,053 2,060 
People having 
sacubitril/valsartan from 
year 2 
24.00% 404 253 494 
This table is adapted from the NICE Resource Tool for guideline TA388 (NICE, 2016b) 
a Value taken from National Clinical Analysis and Specialised Application Team NATCANSAT (2012) 
b Value taken from CQC -Care Quality Commission (2014) 
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 Table 4- Data collection tool for the retrospective study of the use of valsartan/sacubitril in heart failure  
Hospital:  Anonymised Patient ID:  Age: 
Gender: Ethnicity:  
Tick the relevant box and/or fill out the information needed under Details.  
No. Questions: Yes No Details: 
 NICE Guidelines    
1. What was the NYHA classification of the patient prior to 
initiation of Entresto? 
- -  
2. What was the LVEF classification of the patient prior to 
initiation of Entresto? (%) 
- -  
 Refer to question 5 for ACE inhibitor/ARB use    
     
 Patient Medical History    
3. Does the patient have any comorbidities?     
4. If so, specify which of the following the patient has: - -  
A Diabetes    
B Previous Myocardial Infarction (MI)    
C Non-valvular Atrial Fibrillation (NVAF)    
D Valvular Heart Disease (VHD)    
E Previous Stroke or Transient Ishaemic Attack (TIA)    
F Hypertension    
G Device e.g. CRT-D/ICD    
H Coronary Heart Disease (CHD)    
I Chronic Obstructive Pulmonary Disease (COPD)    
J Other (Please state) - -  
5. Was the patient on an ACE inhibitor/ARB prior to 
initiation of Entresto?   
Document drug and dose 
  
 
6. Was the patient on a Beta-blocker (BB) prior to initiation 
of Entresto?    
Document drug and dose 
  
 
7. Was the patient on a diuretic prior to initiation of 
Entresto?  
Document drug and dose 
- - 
 
8. Was the patient on a Mineralocorticoid Receptor 
Antagonist (MRA) prior to initiation of Entresto? 
Document drug and dose 
  
 
9. If the patient wasn’t prescribed an MRA, which of the 
following reasons was the cause: 
- - 
 
A Hyperkalaemia    
B Hypotension    
Table Click here to access/download;Table;Table 4.docx
 C Renal function    
D Sexual side effects/gynaecomastia    
E Other (please state) - -  
F No reason stated     
     
 Entresto Therapy    
10. Date of initiation of Entresto - -  
11. How long has the patient been on Entresto?  
Date of initiation to date of audit or date of 
discontinuation  
  
 
12. Date of discontinuation (if applicable) 
Document reason and alternative prescribed 
- - 
 
13. How did the dose of Entresto change over time? 
 
Dose on initiation: date 
Dose on optimisation: date 
Dose when stabilised: date 
- - 
 
14. What was the NYHA classification of the patient while on 
Entresto? 
- - 
 
15. How many follow-up appointments did the patient have 
with the HF team?  
- - 
 
16. At each point of contact, what was the patient’s 
CrCl (ml/min)? 
K? 
Na? 
BP? 
 
- - 
 
 
  
 
 
 
 
